Search results
Pfizer sees lung cancer drug topping $1 billion in sales following impressive 5-year data
Reuters via AOL· 4 days agoPfizer said it expects its cancer drug Lorbrena to top $1 billion in annual sales by 2030 on the...
Pfizer (PFE) Up 1.8% Since Last Earnings Report: Can It Continue?
Zacks via Yahoo Finance· 4 days agoExcluding revenues from Seagen and the abovementioned reclassification, the revenue guidance for...
Pfizer says its its lung cancer drug Lorbrena could be a $1 billion blockbuster
Quartz· 4 days agoPharma giant Pfizer said that its lung cancer drug Lorbrena could reach blockbuster status by 2030...
Retirement Roadblocks: 7 Stocks to Avoid as You Near the Finish Line
InvestorPlace· 20 hours agoAs you approach retirement, it’s crucial to carefully consider your investment portfolio and make...
2 Beaten-Down Dividend Stocks Near 52-Week Lows. Should You Buy the Dips?
Motley Fool via Yahoo Finance· 7 days agoThe 10 stocks that made the cut could produce monster returns in the coming years. Consider when...
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend...
Benzinga· 7 days agoThis analyst has an accuracy...warn non-white patients about health risks associated with their...
3 Discounted Stocks Poised for a Major Upswing
InvestorPlace· 2 days agoRecent financial results for the first one show robust revenue growth and enhanced gross margins, underpinned by efficient cost control. Rising revenue per user and lower ...
Ginkgo Bioworks Stock: Bull vs. Bear
Motley Fool via Yahoo Finance· 4 days agoKeith Speights has positions in Pfizer. The Motley Fool has positions in and recommends Pfizer. The Motley Fool has a disclosure policy. Ginkgo Bioworks...
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
Investor's Business Daily· 4 days agoThe drug, now known as Casgevy, will cost $2.2 million for a single treatment. But uptake remains to...
Exact Sciences (EXAS) Witnesses Rising Expenses, Competition
Zacks via Yahoo Finance· 6 days agoOn a positive note, the company is confident about capturing at least 40% of the U.S. colorectal...
